CCT251545 profile

CCT251545: a Wnt signaling inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

CCT251545 : A chloropyridine that is 3-chloropyridine substituted by a 1-oxo-2,8-diazaspiro[4.5]decan-8-yl group and a 4-(1-methyl-1H-pyrazol-4-yl)phenyl group at positions 4 and 5, respectively. It is an orally bioavailable inhibitor of Wnt signaling (IC50 = 5 nM) and a potent and selective chemical probe for cyclin-dependent kinases CDK8 and CDK19. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	77050682
CHEMBL ID	3408213
CHEBI ID	143114
SCHEMBL ID	17113515

Synonym
8-[3-chloro-5-[4-(1-methylpyrazol-4-yl)phenyl]pyridin-4-yl]-2,8-diazaspiro[4.5]decan-1-one
8-[3-chloro-5-[4-(1-methyl-1h-pyrazole-4-yl)phenyl]-4-pyridyl]-2,8-diazaspiro[4.5]decane-1-one
CHEBI:143114
1661839-45-7
cct251545
8-{3-chloro-5-[4-(1-methyl-1h-pyrazol-4-yl)phenyl]pyridin-4-yl}-2,8-diazaspiro[4.5]decan-1-one
S7981
8-(3-chloro-5-(4-(1-methyl-1h-pyrazol-4-yl)phenyl)pyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one
4tv ,
CS-5359
HY-12681
AC-31717
SCHEMBL17113515
gtpl8945
bdbm50073190
CHEMBL3408213 ,
AKOS030526639
BCP17378
cct-251545;cct 251545
EX-A2539
Q27075796
AMY16654
nsc-784591
nsc784591
cct 251545
MS-27406
cct-251545
2,8-diazaspiro[4.5]decan-1-one, 8-[3-chloro-5-[4-(1-methyl-1h-pyrazol-4-yl)phenyl]-4-pyridinyl]-
A902314
8-{3-chloro-5-[4-(1-methyl-1h-pyrazol-4-yl)-phenyl]-
pyridin-4-yl}-2,8-diaza-spiro[4.5]decan-1-one
8-{3-chloro-5-[4-(1-methyl-1h-pyrazol-4-yl)-phenyl]- pyridin-4-yl}-2,8-diaza-spiro[4.5]decan-1-one

Excerpt	Reference	Relevance
" Here we report the discovery of 109 (CCT251921), a potent, selective, and orally bioavailable inhibitor of CDK8 with equipotent affinity for CDK19."	( Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19. Adeniji-Popoola, O; Blagg, J; Burke, R; Busch, M; Calderini, M; Clarke, PA; Crumpler, S; Czodrowski, P; Dale, T; de Haven Brandon, A; Eccles, SA; Esdar, C; Mallinger, A; Musil, D; Ortiz-Ruiz, MJ; Poeschke, O; Raynaud, FI; Rink, C; Rohdich, F; Schiemann, K; Schneider, R; Schwarz, D; Stieber, F; Stubbs, M; Thai, C; Valenti, M; Wienke, D; Workman, P, 2016)	0.43

Role	Description
Wnt signalling inhibitor	A substance that inhibits any of the Wnt signalling pathway, a group of signal transduction pathways made of proteins that pass signals from outside of a cell through cell surface receptors to the inside of the cell.
antineoplastic agent	A substance that inhibits or prevents the proliferation of neoplasms.
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor	An EC 2.7.11.* (protein-serine/threonine kinase) inhibitor that interferes with the action of cyclin-dependent kinase (EC 2.7.11.22).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
chloropyridine	Compounds containing a pyridine nucleus substituted with one or more chlorine atoms.
pyrazoles
azaspiro compound	An azaspiro compound is a spiro compound in which at least one of the cyclic components is a nitrogen heterocyle.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
PPM1D protein	Homo sapiens (human)	Potency	0.0370	0.0052	9.4661	32.9993	AID1347411
Interferon beta	Homo sapiens (human)	Potency	0.0370	0.0033	9.1582	39.8107	AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Poly [ADP-ribose] polymerase tankyrase-1	Homo sapiens (human)	IC50 (µMol)	10.0000	0.0019	0.6293	5.0000	AID1198325
Cyclin-C	Homo sapiens (human)	IC50 (µMol)	0.0060	0.0050	0.6792	5.9000	AID1295765
Cyclin-C	Homo sapiens (human)	Ki	0.0090	0.0090	0.0090	0.0090	AID1731776
Cyclin-dependent kinase 8	Homo sapiens (human)	IC50 (µMol)	0.0169	0.0034	1.0275	5.9000	AID1295749; AID1295764; AID1852092
Cyclin-dependent kinase 8	Homo sapiens (human)	Ki	0.0090	0.0090	0.0090	0.0090	AID1731776
Glycogen synthase kinase-3 alpha	Homo sapiens (human)	IC50 (µMol)	0.4620	0.0010	1.2249	9.1000	AID1198336
Glycogen synthase kinase-3 alpha	Homo sapiens (human)	Ki	0.2310	0.0091	0.3468	1.6000	AID1731798
Glycogen synthase kinase-3 beta	Homo sapiens (human)	IC50 (µMol)	0.6900	0.0006	0.8013	10.0000	AID1198337
Glycogen synthase kinase-3 beta	Homo sapiens (human)	Ki	0.3450	0.0020	0.3668	1.6000	AID1731799
Protein Wnt-3a	Homo sapiens (human)	IC50 (µMol)	0.0070	0.0035	0.0295	0.0780	AID1198342
Protein kinase C theta type	Homo sapiens (human)	Ki	0.0610	0.0015	0.6503	6.0000	AID1731800
Cyclin-dependent kinase 19	Homo sapiens (human)	IC50 (µMol)	0.0055	0.0050	0.4085	2.2000	AID1295749; AID1295765
Poly [ADP-ribose] polymerase tankyrase-2	Homo sapiens (human)	IC50 (µMol)	15.0000	0.0021	0.6750	5.1300	AID1198326
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Cyclin-dependent kinase 19	Mus musculus (house mouse)	EC50 (µMol)	0.0200	0.0200	0.0200	0.0200	AID1733982
Cyclin-dependent kinase 8	Mus musculus (house mouse)	EC50 (µMol)	0.0200	0.0200	0.7100	1.4000	AID1733982
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
peptidyl-serine phosphorylation	Poly [ADP-ribose] polymerase tankyrase-1	Homo sapiens (human)
peptidyl-threonine phosphorylation	Poly [ADP-ribose] polymerase tankyrase-1	Homo sapiens (human)
protein polyubiquitination	Poly [ADP-ribose] polymerase tankyrase-1	Homo sapiens (human)
mitotic spindle organization	Poly [ADP-ribose] polymerase tankyrase-1	Homo sapiens (human)
protein transport	Poly [ADP-ribose] polymerase tankyrase-1	Homo sapiens (human)
Wnt signaling pathway	Poly [ADP-ribose] polymerase tankyrase-1	Homo sapiens (human)
regulation of telomere maintenance via telomerase	Poly [ADP-ribose] polymerase tankyrase-1	Homo sapiens (human)
positive regulation of telomere maintenance via telomerase	Poly [ADP-ribose] polymerase tankyrase-1	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Poly [ADP-ribose] polymerase tankyrase-1	Homo sapiens (human)
mRNA transport	Poly [ADP-ribose] polymerase tankyrase-1	Homo sapiens (human)
spindle assembly	Poly [ADP-ribose] polymerase tankyrase-1	Homo sapiens (human)
cell division	Poly [ADP-ribose] polymerase tankyrase-1	Homo sapiens (human)
positive regulation of telomerase activity	Poly [ADP-ribose] polymerase tankyrase-1	Homo sapiens (human)
protein localization to chromosome, telomeric region	Poly [ADP-ribose] polymerase tankyrase-1	Homo sapiens (human)
protein poly-ADP-ribosylation	Poly [ADP-ribose] polymerase tankyrase-1	Homo sapiens (human)
protein auto-ADP-ribosylation	Poly [ADP-ribose] polymerase tankyrase-1	Homo sapiens (human)
positive regulation of canonical Wnt signaling pathway	Poly [ADP-ribose] polymerase tankyrase-1	Homo sapiens (human)
positive regulation of telomere capping	Poly [ADP-ribose] polymerase tankyrase-1	Homo sapiens (human)
negative regulation of telomere maintenance via telomere lengthening	Poly [ADP-ribose] polymerase tankyrase-1	Homo sapiens (human)
negative regulation of telomeric DNA binding	Poly [ADP-ribose] polymerase tankyrase-1	Homo sapiens (human)
negative regulation of maintenance of mitotic sister chromatid cohesion, telomeric	Poly [ADP-ribose] polymerase tankyrase-1	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
G0 to G1 transition	Cyclin-C	Homo sapiens (human)
negative regulation of Notch signaling pathway	Cyclin-C	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cyclin-C	Homo sapiens (human)
protein ubiquitination	Cyclin-dependent kinase 8	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cyclin-dependent kinase 8	Homo sapiens (human)
regulation of cell cycle	Cyclin-dependent kinase 8	Homo sapiens (human)
negative regulation of triglyceride metabolic process	Cyclin-dependent kinase 8	Homo sapiens (human)
protein phosphorylation	Cyclin-dependent kinase 8	Homo sapiens (human)
regulation of systemic arterial blood pressure	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
cardiac left ventricle morphogenesis	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
glycogen metabolic process	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
protein phosphorylation	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
dopamine receptor signaling pathway	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
nervous system development	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
insulin receptor signaling pathway	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of autophagy	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of gene expression	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of peptidyl-threonine phosphorylation	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
negative regulation of UDP-glucose catabolic process	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
Wnt signaling pathway	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
cell migration	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
peptidyl-threonine phosphorylation	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
viral protein processing	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of protein ubiquitination	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
negative regulation of TOR signaling	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic process	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
cellular response to insulin stimulus	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
cellular response to interleukin-3	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
negative regulation of glycogen biosynthetic process	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of protein catabolic process	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of heart contraction	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
negative regulation of glucose import	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
negative regulation of insulin receptor signaling pathway	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
excitatory postsynaptic potential	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
negative regulation of cell growth involved in cardiac muscle cell development	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
cellular response to lithium ion	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
cellular response to glucocorticoid stimulus	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of adenylate cyclase-activating adrenergic receptor signaling pathway	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
negative regulation of canonical Wnt signaling pathway	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
extrinsic apoptotic signaling pathway	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligand	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
autosome genomic imprinting	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
regulation of mitophagy	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of amyloid-beta formation	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of protein targeting to mitochondrion	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
negative regulation of glycogen synthase activity, transferring glucose-1-phosphate	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
negative regulation of type B pancreatic cell development	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
negative regulation of glycogen (starch) synthase activity	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of glycogen (starch) synthase activity	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
cell differentiation	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
regulation of microtubule cytoskeleton organization	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
regulation of neuron projection development	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of gene expression	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of gene expression	Glycogen synthase kinase-3 beta	Homo sapiens (human)
ER overload response	Glycogen synthase kinase-3 beta	Homo sapiens (human)
peptidyl-serine phosphorylation	Glycogen synthase kinase-3 beta	Homo sapiens (human)
intracellular signal transduction	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of apoptotic process	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of protein export from nucleus	Glycogen synthase kinase-3 beta	Homo sapiens (human)
epithelial to mesenchymal transition	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of cell-matrix adhesion	Glycogen synthase kinase-3 beta	Homo sapiens (human)
glycogen metabolic process	Glycogen synthase kinase-3 beta	Homo sapiens (human)
protein phosphorylation	Glycogen synthase kinase-3 beta	Homo sapiens (human)
mitochondrion organization	Glycogen synthase kinase-3 beta	Homo sapiens (human)
dopamine receptor signaling pathway	Glycogen synthase kinase-3 beta	Homo sapiens (human)
circadian rhythm	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of autophagy	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of gene expression	Glycogen synthase kinase-3 beta	Homo sapiens (human)
peptidyl-serine phosphorylation	Glycogen synthase kinase-3 beta	Homo sapiens (human)
peptidyl-threonine phosphorylation	Glycogen synthase kinase-3 beta	Homo sapiens (human)
viral protein processing	Glycogen synthase kinase-3 beta	Homo sapiens (human)
hippocampus development	Glycogen synthase kinase-3 beta	Homo sapiens (human)
establishment of cell polarity	Glycogen synthase kinase-3 beta	Homo sapiens (human)
maintenance of cell polarity	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of cell migration	Glycogen synthase kinase-3 beta	Homo sapiens (human)
regulation of axon extension	Glycogen synthase kinase-3 beta	Homo sapiens (human)
neuron projection development	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of protein-containing complex assembly	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of protein-containing complex assembly	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of protein ubiquitination	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of protein binding	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic process	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of phosphoprotein phosphatase activity	Glycogen synthase kinase-3 beta	Homo sapiens (human)
regulation of microtubule-based process	Glycogen synthase kinase-3 beta	Homo sapiens (human)
intracellular signal transduction	Glycogen synthase kinase-3 beta	Homo sapiens (human)
cellular response to interleukin-3	Glycogen synthase kinase-3 beta	Homo sapiens (human)
regulation of circadian rhythm	Glycogen synthase kinase-3 beta	Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of GTPase activity	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of cell differentiation	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of osteoblast differentiation	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of glycogen biosynthetic process	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of cilium assembly	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of protein catabolic process	Glycogen synthase kinase-3 beta	Homo sapiens (human)
protein autophosphorylation	Glycogen synthase kinase-3 beta	Homo sapiens (human)
regulation of protein export from nucleus	Glycogen synthase kinase-3 beta	Homo sapiens (human)
regulation of dendrite morphogenesis	Glycogen synthase kinase-3 beta	Homo sapiens (human)
regulation of axonogenesis	Glycogen synthase kinase-3 beta	Homo sapiens (human)
canonical Wnt signaling pathway	Glycogen synthase kinase-3 beta	Homo sapiens (human)
excitatory postsynaptic potential	Glycogen synthase kinase-3 beta	Homo sapiens (human)
regulation of microtubule cytoskeleton organization	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of calcineurin-NFAT signaling cascade	Glycogen synthase kinase-3 beta	Homo sapiens (human)
superior temporal gyrus development	Glycogen synthase kinase-3 beta	Homo sapiens (human)
cellular response to retinoic acid	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of canonical Wnt signaling pathway	Glycogen synthase kinase-3 beta	Homo sapiens (human)
extrinsic apoptotic signaling pathway	Glycogen synthase kinase-3 beta	Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligand	Glycogen synthase kinase-3 beta	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	Glycogen synthase kinase-3 beta	Homo sapiens (human)
neuron projection organization	Glycogen synthase kinase-3 beta	Homo sapiens (human)
regulation of microtubule anchoring at centrosome	Glycogen synthase kinase-3 beta	Homo sapiens (human)
regulation of cellular response to heat	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of protein localization to nucleus	Glycogen synthase kinase-3 beta	Homo sapiens (human)
regulation of long-term synaptic potentiation	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of protein acetylation	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway via death domain receptors	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of protein localization to cilium	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of dopaminergic neuron differentiation	Glycogen synthase kinase-3 beta	Homo sapiens (human)
cellular response to amyloid-beta	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of protein localization to centrosome	Glycogen synthase kinase-3 beta	Homo sapiens (human)
beta-catenin destruction complex disassembly	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of type B pancreatic cell development	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of glycogen (starch) synthase activity	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of mesenchymal stem cell differentiation	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of TOR signaling	Glycogen synthase kinase-3 beta	Homo sapiens (human)
regulation of neuron projection development	Glycogen synthase kinase-3 beta	Homo sapiens (human)
cell differentiation	Glycogen synthase kinase-3 beta	Homo sapiens (human)
insulin receptor signaling pathway	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of cardiac muscle cell differentiation	Protein Wnt-3a	Homo sapiens (human)
osteoblast differentiation	Protein Wnt-3a	Homo sapiens (human)
in utero embryonic development	Protein Wnt-3a	Homo sapiens (human)
positive regulation of cytokine production	Protein Wnt-3a	Homo sapiens (human)
positive regulation of protein phosphorylation	Protein Wnt-3a	Homo sapiens (human)
heart looping	Protein Wnt-3a	Homo sapiens (human)
positive regulation of receptor internalization	Protein Wnt-3a	Homo sapiens (human)
transcription by RNA polymerase II	Protein Wnt-3a	Homo sapiens (human)
axon guidance	Protein Wnt-3a	Homo sapiens (human)
heart development	Protein Wnt-3a	Homo sapiens (human)
protein localization	Protein Wnt-3a	Homo sapiens (human)
cell population proliferation	Protein Wnt-3a	Homo sapiens (human)
positive regulation of cell population proliferation	Protein Wnt-3a	Homo sapiens (human)
COP9 signalosome assembly	Protein Wnt-3a	Homo sapiens (human)
positive regulation of gene expression	Protein Wnt-3a	Homo sapiens (human)
negative regulation of neuron projection development	Protein Wnt-3a	Homo sapiens (human)
spinal cord association neuron differentiation	Protein Wnt-3a	Homo sapiens (human)
hippocampus development	Protein Wnt-3a	Homo sapiens (human)
cell proliferation in forebrain	Protein Wnt-3a	Homo sapiens (human)
Wnt signaling pathway involved in forebrain neuroblast division	Protein Wnt-3a	Homo sapiens (human)
dorsal/ventral neural tube patterning	Protein Wnt-3a	Homo sapiens (human)
hemopoiesis	Protein Wnt-3a	Homo sapiens (human)
neuron differentiation	Protein Wnt-3a	Homo sapiens (human)
extracellular matrix organization	Protein Wnt-3a	Homo sapiens (human)
mammary gland development	Protein Wnt-3a	Homo sapiens (human)
positive regulation of B cell proliferation	Protein Wnt-3a	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Protein Wnt-3a	Homo sapiens (human)
cell proliferation in midbrain	Protein Wnt-3a	Homo sapiens (human)
non-canonical Wnt signaling pathway	Protein Wnt-3a	Homo sapiens (human)
skeletal muscle cell differentiation	Protein Wnt-3a	Homo sapiens (human)
post-anal tail morphogenesis	Protein Wnt-3a	Homo sapiens (human)
synaptic vesicle recycling	Protein Wnt-3a	Homo sapiens (human)
B cell proliferation	Protein Wnt-3a	Homo sapiens (human)
inner ear morphogenesis	Protein Wnt-3a	Homo sapiens (human)
fat cell differentiation	Protein Wnt-3a	Homo sapiens (human)
myoblast differentiation	Protein Wnt-3a	Homo sapiens (human)
negative regulation of fat cell differentiation	Protein Wnt-3a	Homo sapiens (human)
positive regulation of DNA-templated transcription	Protein Wnt-3a	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Protein Wnt-3a	Homo sapiens (human)
somatic stem cell division	Protein Wnt-3a	Homo sapiens (human)
positive regulation of mesodermal cell fate specification	Protein Wnt-3a	Homo sapiens (human)
paraxial mesodermal cell fate commitment	Protein Wnt-3a	Homo sapiens (human)
positive regulation of skeletal muscle tissue development	Protein Wnt-3a	Homo sapiens (human)
positive regulation of collateral sprouting in absence of injury	Protein Wnt-3a	Homo sapiens (human)
negative regulation of axon extension involved in axon guidance	Protein Wnt-3a	Homo sapiens (human)
negative regulation of neurogenesis	Protein Wnt-3a	Homo sapiens (human)
modulation of chemical synaptic transmission	Protein Wnt-3a	Homo sapiens (human)
regulation of synapse organization	Protein Wnt-3a	Homo sapiens (human)
canonical Wnt signaling pathway	Protein Wnt-3a	Homo sapiens (human)
cardiac muscle cell fate commitment	Protein Wnt-3a	Homo sapiens (human)
positive regulation of dermatome development	Protein Wnt-3a	Homo sapiens (human)
secondary palate development	Protein Wnt-3a	Homo sapiens (human)
regulation of microtubule cytoskeleton organization	Protein Wnt-3a	Homo sapiens (human)
platelet aggregation	Protein Wnt-3a	Homo sapiens (human)
cellular response to retinoic acid	Protein Wnt-3a	Homo sapiens (human)
axis elongation involved in somitogenesis	Protein Wnt-3a	Homo sapiens (human)
positive regulation of canonical Wnt signaling pathway	Protein Wnt-3a	Homo sapiens (human)
calcium ion transmembrane transport via low voltage-gated calcium channel	Protein Wnt-3a	Homo sapiens (human)
presynapse assembly	Protein Wnt-3a	Homo sapiens (human)
positive regulation of protein localization to plasma membrane	Protein Wnt-3a	Homo sapiens (human)
negative regulation of dopaminergic neuron differentiation	Protein Wnt-3a	Homo sapiens (human)
midbrain dopaminergic neuron differentiation	Protein Wnt-3a	Homo sapiens (human)
regulation of postsynapse to nucleus signaling pathway	Protein Wnt-3a	Homo sapiens (human)
regulation of presynapse assembly	Protein Wnt-3a	Homo sapiens (human)
positive regulation of cell-cell adhesion mediated by cadherin	Protein Wnt-3a	Homo sapiens (human)
positive regulation of neural precursor cell proliferation	Protein Wnt-3a	Homo sapiens (human)
positive regulation of hepatocyte proliferation	Protein Wnt-3a	Homo sapiens (human)
cell fate commitment	Protein Wnt-3a	Homo sapiens (human)
regulation of cell growth	Protein kinase C theta type	Homo sapiens (human)
regulation of DNA-templated transcription	Protein kinase C theta type	Homo sapiens (human)
protein phosphorylation	Protein kinase C theta type	Homo sapiens (human)
membrane protein ectodomain proteolysis	Protein kinase C theta type	Homo sapiens (human)
inflammatory response	Protein kinase C theta type	Homo sapiens (human)
axon guidance	Protein kinase C theta type	Homo sapiens (human)
positive regulation of telomere maintenance via telomerase	Protein kinase C theta type	Homo sapiens (human)
positive regulation of interleukin-17 production	Protein kinase C theta type	Homo sapiens (human)
positive regulation of interleukin-2 production	Protein kinase C theta type	Homo sapiens (human)
positive regulation of interleukin-4 production	Protein kinase C theta type	Homo sapiens (human)
intracellular signal transduction	Protein kinase C theta type	Homo sapiens (human)
CD4-positive, alpha-beta T cell proliferation	Protein kinase C theta type	Homo sapiens (human)
Fc-epsilon receptor signaling pathway	Protein kinase C theta type	Homo sapiens (human)
negative regulation of insulin receptor signaling pathway	Protein kinase C theta type	Homo sapiens (human)
positive regulation of T cell activation	Protein kinase C theta type	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Protein kinase C theta type	Homo sapiens (human)
positive regulation of telomerase activity	Protein kinase C theta type	Homo sapiens (human)
cell chemotaxis	Protein kinase C theta type	Homo sapiens (human)
negative regulation of T cell apoptotic process	Protein kinase C theta type	Homo sapiens (human)
regulation of platelet aggregation	Protein kinase C theta type	Homo sapiens (human)
positive regulation of telomere capping	Protein kinase C theta type	Homo sapiens (human)
positive regulation of T-helper 17 type immune response	Protein kinase C theta type	Homo sapiens (human)
positive regulation of CD4-positive, alpha-beta T cell proliferation	Protein kinase C theta type	Homo sapiens (human)
positive regulation of T-helper 2 cell activation	Protein kinase C theta type	Homo sapiens (human)
peptidyl-serine phosphorylation	Protein kinase C theta type	Homo sapiens (human)
positive regulation of apoptotic process	Cyclin-dependent kinase 19	Homo sapiens (human)
regulation of cell cycle	Cyclin-dependent kinase 19	Homo sapiens (human)
cellular response to lipopolysaccharide	Cyclin-dependent kinase 19	Homo sapiens (human)
protein phosphorylation	Cyclin-dependent kinase 19	Homo sapiens (human)
protein polyubiquitination	Poly [ADP-ribose] polymerase tankyrase-2	Homo sapiens (human)
Wnt signaling pathway	Poly [ADP-ribose] polymerase tankyrase-2	Homo sapiens (human)
positive regulation of telomere maintenance via telomerase	Poly [ADP-ribose] polymerase tankyrase-2	Homo sapiens (human)
protein localization to chromosome, telomeric region	Poly [ADP-ribose] polymerase tankyrase-2	Homo sapiens (human)
protein poly-ADP-ribosylation	Poly [ADP-ribose] polymerase tankyrase-2	Homo sapiens (human)
protein auto-ADP-ribosylation	Poly [ADP-ribose] polymerase tankyrase-2	Homo sapiens (human)
positive regulation of canonical Wnt signaling pathway	Poly [ADP-ribose] polymerase tankyrase-2	Homo sapiens (human)
positive regulation of telomere capping	Poly [ADP-ribose] polymerase tankyrase-2	Homo sapiens (human)
negative regulation of telomere maintenance via telomere lengthening	Poly [ADP-ribose] polymerase tankyrase-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
NAD+ ADP-ribosyltransferase activity	Poly [ADP-ribose] polymerase tankyrase-1	Homo sapiens (human)
protein binding	Poly [ADP-ribose] polymerase tankyrase-1	Homo sapiens (human)
zinc ion binding	Poly [ADP-ribose] polymerase tankyrase-1	Homo sapiens (human)
nucleotidyltransferase activity	Poly [ADP-ribose] polymerase tankyrase-1	Homo sapiens (human)
histone binding	Poly [ADP-ribose] polymerase tankyrase-1	Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activity	Poly [ADP-ribose] polymerase tankyrase-1	Homo sapiens (human)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
protein binding	Cyclin-C	Homo sapiens (human)
identical protein binding	Cyclin-C	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase regulator activity	Cyclin-C	Homo sapiens (human)
protein kinase activity	Cyclin-dependent kinase 8	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activity	Cyclin-dependent kinase 8	Homo sapiens (human)
protein binding	Cyclin-dependent kinase 8	Homo sapiens (human)
ATP binding	Cyclin-dependent kinase 8	Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activity	Cyclin-dependent kinase 8	Homo sapiens (human)
ubiquitin protein ligase activity	Cyclin-dependent kinase 8	Homo sapiens (human)
protein serine kinase activity	Cyclin-dependent kinase 8	Homo sapiens (human)
protein serine/threonine kinase activity	Cyclin-dependent kinase 8	Homo sapiens (human)
protein serine/threonine kinase activity	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
signaling receptor binding	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
protein binding	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
ATP binding	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
protein kinase A catalytic subunit binding	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
tau protein binding	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
tau-protein kinase activity	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
protein serine kinase activity	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
protease binding	Glycogen synthase kinase-3 beta	Homo sapiens (human)
p53 binding	Glycogen synthase kinase-3 beta	Homo sapiens (human)
protein kinase activity	Glycogen synthase kinase-3 beta	Homo sapiens (human)
protein serine/threonine kinase activity	Glycogen synthase kinase-3 beta	Homo sapiens (human)
protein binding	Glycogen synthase kinase-3 beta	Homo sapiens (human)
ATP binding	Glycogen synthase kinase-3 beta	Homo sapiens (human)
beta-catenin binding	Glycogen synthase kinase-3 beta	Homo sapiens (human)
kinase activity	Glycogen synthase kinase-3 beta	Homo sapiens (human)
protein kinase binding	Glycogen synthase kinase-3 beta	Homo sapiens (human)
ubiquitin protein ligase binding	Glycogen synthase kinase-3 beta	Homo sapiens (human)
protein kinase A catalytic subunit binding	Glycogen synthase kinase-3 beta	Homo sapiens (human)
dynactin binding	Glycogen synthase kinase-3 beta	Homo sapiens (human)
tau protein binding	Glycogen synthase kinase-3 beta	Homo sapiens (human)
tau-protein kinase activity	Glycogen synthase kinase-3 beta	Homo sapiens (human)
NF-kappaB binding	Glycogen synthase kinase-3 beta	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Glycogen synthase kinase-3 beta	Homo sapiens (human)
protein serine kinase activity	Glycogen synthase kinase-3 beta	Homo sapiens (human)
transcription coactivator activity	Protein Wnt-3a	Homo sapiens (human)
signaling receptor binding	Protein Wnt-3a	Homo sapiens (human)
protein binding	Protein Wnt-3a	Homo sapiens (human)
protein domain specific binding	Protein Wnt-3a	Homo sapiens (human)
co-receptor binding	Protein Wnt-3a	Homo sapiens (human)
identical protein binding	Protein Wnt-3a	Homo sapiens (human)
receptor ligand activity	Protein Wnt-3a	Homo sapiens (human)
cytokine activity	Protein Wnt-3a	Homo sapiens (human)
frizzled binding	Protein Wnt-3a	Homo sapiens (human)
protein kinase activity	Protein kinase C theta type	Homo sapiens (human)
protein serine/threonine kinase activity	Protein kinase C theta type	Homo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activity	Protein kinase C theta type	Homo sapiens (human)
protein binding	Protein kinase C theta type	Homo sapiens (human)
ATP binding	Protein kinase C theta type	Homo sapiens (human)
metal ion binding	Protein kinase C theta type	Homo sapiens (human)
protein serine kinase activity	Protein kinase C theta type	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activity	Cyclin-dependent kinase 19	Homo sapiens (human)
ATP binding	Cyclin-dependent kinase 19	Homo sapiens (human)
protein serine kinase activity	Cyclin-dependent kinase 19	Homo sapiens (human)
protein serine/threonine kinase activity	Cyclin-dependent kinase 19	Homo sapiens (human)
NAD+ ADP-ribosyltransferase activity	Poly [ADP-ribose] polymerase tankyrase-2	Homo sapiens (human)
protein binding	Poly [ADP-ribose] polymerase tankyrase-2	Homo sapiens (human)
nucleotidyltransferase activity	Poly [ADP-ribose] polymerase tankyrase-2	Homo sapiens (human)
enzyme binding	Poly [ADP-ribose] polymerase tankyrase-2	Homo sapiens (human)
metal ion binding	Poly [ADP-ribose] polymerase tankyrase-2	Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activity	Poly [ADP-ribose] polymerase tankyrase-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
Golgi membrane	Poly [ADP-ribose] polymerase tankyrase-1	Homo sapiens (human)
pericentriolar material	Poly [ADP-ribose] polymerase tankyrase-1	Homo sapiens (human)
chromosome, telomeric region	Poly [ADP-ribose] polymerase tankyrase-1	Homo sapiens (human)
nucleoplasm	Poly [ADP-ribose] polymerase tankyrase-1	Homo sapiens (human)
Golgi apparatus	Poly [ADP-ribose] polymerase tankyrase-1	Homo sapiens (human)
cytosol	Poly [ADP-ribose] polymerase tankyrase-1	Homo sapiens (human)
nuclear body	Poly [ADP-ribose] polymerase tankyrase-1	Homo sapiens (human)
nuclear membrane	Poly [ADP-ribose] polymerase tankyrase-1	Homo sapiens (human)
mitotic spindle pole	Poly [ADP-ribose] polymerase tankyrase-1	Homo sapiens (human)
nuclear pore	Poly [ADP-ribose] polymerase tankyrase-1	Homo sapiens (human)
nucleus	Poly [ADP-ribose] polymerase tankyrase-1	Homo sapiens (human)
cytoplasm	Poly [ADP-ribose] polymerase tankyrase-1	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complex	Cyclin-C	Homo sapiens (human)
nucleoplasm	Cyclin-C	Homo sapiens (human)
CKM complex	Cyclin-C	Homo sapiens (human)
nucleus	Cyclin-C	Homo sapiens (human)
mediator complex	Cyclin-C	Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complex	Cyclin-dependent kinase 8	Homo sapiens (human)
nucleus	Cyclin-dependent kinase 8	Homo sapiens (human)
nucleoplasm	Cyclin-dependent kinase 8	Homo sapiens (human)
nucleolus	Cyclin-dependent kinase 8	Homo sapiens (human)
CKM complex	Cyclin-dependent kinase 8	Homo sapiens (human)
ubiquitin ligase complex	Cyclin-dependent kinase 8	Homo sapiens (human)
mediator complex	Cyclin-dependent kinase 8	Homo sapiens (human)
protein-containing complex	Cyclin-dependent kinase 8	Homo sapiens (human)
nucleus	Cyclin-dependent kinase 8	Homo sapiens (human)
mitochondrion	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
cytosol	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
beta-catenin destruction complex	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
neuronal cell body	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
apical dendrite	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
postsynapse	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
proximal dendrite	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
cytoplasm	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
nucleus	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
axon	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
cytosol	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
glutamatergic synapse	Glycogen synthase kinase-3 beta	Homo sapiens (human)
nucleus	Glycogen synthase kinase-3 beta	Homo sapiens (human)
nucleoplasm	Glycogen synthase kinase-3 beta	Homo sapiens (human)
cytoplasm	Glycogen synthase kinase-3 beta	Homo sapiens (human)
mitochondrion	Glycogen synthase kinase-3 beta	Homo sapiens (human)
centrosome	Glycogen synthase kinase-3 beta	Homo sapiens (human)
cytosol	Glycogen synthase kinase-3 beta	Homo sapiens (human)
plasma membrane	Glycogen synthase kinase-3 beta	Homo sapiens (human)
axon	Glycogen synthase kinase-3 beta	Homo sapiens (human)
dendrite	Glycogen synthase kinase-3 beta	Homo sapiens (human)
beta-catenin destruction complex	Glycogen synthase kinase-3 beta	Homo sapiens (human)
presynapse	Glycogen synthase kinase-3 beta	Homo sapiens (human)
postsynapse	Glycogen synthase kinase-3 beta	Homo sapiens (human)
Wnt signalosome	Glycogen synthase kinase-3 beta	Homo sapiens (human)
cytosol	Glycogen synthase kinase-3 beta	Homo sapiens (human)
axon	Glycogen synthase kinase-3 beta	Homo sapiens (human)
nucleus	Glycogen synthase kinase-3 beta	Homo sapiens (human)
cytoplasm	Glycogen synthase kinase-3 beta	Homo sapiens (human)
glutamatergic synapse	Protein Wnt-3a	Homo sapiens (human)
extracellular region	Protein Wnt-3a	Homo sapiens (human)
extracellular space	Protein Wnt-3a	Homo sapiens (human)
endoplasmic reticulum lumen	Protein Wnt-3a	Homo sapiens (human)
Golgi lumen	Protein Wnt-3a	Homo sapiens (human)
plasma membrane	Protein Wnt-3a	Homo sapiens (human)
cell surface	Protein Wnt-3a	Homo sapiens (human)
endocytic vesicle membrane	Protein Wnt-3a	Homo sapiens (human)
early endosome membrane	Protein Wnt-3a	Homo sapiens (human)
extracellular exosome	Protein Wnt-3a	Homo sapiens (human)
presynapse	Protein Wnt-3a	Homo sapiens (human)
Wnt-Frizzled-LRP5/6 complex	Protein Wnt-3a	Homo sapiens (human)
extracellular space	Protein Wnt-3a	Homo sapiens (human)
immunological synapse	Protein kinase C theta type	Homo sapiens (human)
cytosol	Protein kinase C theta type	Homo sapiens (human)
plasma membrane	Protein kinase C theta type	Homo sapiens (human)
aggresome	Protein kinase C theta type	Homo sapiens (human)
centriolar satellite	Protein kinase C theta type	Homo sapiens (human)
nucleoplasm	Cyclin-dependent kinase 8	Mus musculus (house mouse)
nucleoplasm	Cyclin-dependent kinase 19	Homo sapiens (human)
cytosol	Cyclin-dependent kinase 19	Homo sapiens (human)
perinuclear region of cytoplasm	Cyclin-dependent kinase 19	Homo sapiens (human)
CKM complex	Cyclin-dependent kinase 19	Homo sapiens (human)
nucleus	Cyclin-dependent kinase 19	Homo sapiens (human)
cytosol	Cyclin-dependent kinase 19	Homo sapiens (human)
Golgi membrane	Poly [ADP-ribose] polymerase tankyrase-2	Homo sapiens (human)
pericentriolar material	Poly [ADP-ribose] polymerase tankyrase-2	Homo sapiens (human)
chromosome, telomeric region	Poly [ADP-ribose] polymerase tankyrase-2	Homo sapiens (human)
nucleus	Poly [ADP-ribose] polymerase tankyrase-2	Homo sapiens (human)
nuclear envelope	Poly [ADP-ribose] polymerase tankyrase-2	Homo sapiens (human)
cytoplasm	Poly [ADP-ribose] polymerase tankyrase-2	Homo sapiens (human)
cytosol	Poly [ADP-ribose] polymerase tankyrase-2	Homo sapiens (human)
perinuclear region of cytoplasm	Poly [ADP-ribose] polymerase tankyrase-2	Homo sapiens (human)
cytoplasm	Poly [ADP-ribose] polymerase tankyrase-2	Homo sapiens (human)
nucleus	Poly [ADP-ribose] polymerase tankyrase-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (140)

Assay ID	Title	Year	Journal	Article
AID1731804	Growth inhibition human KG-1a cells after 72 hrs by resazurin or MTT assay	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1295778	Inhibition of WNT pathway activation in human COLO205 cells expressing APC mutant	2016	Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3	Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.
AID1731798	Inhibition of human GSKalpha S449A mutant (2 to 3nd residues) using YRRAAVPPSPSLSRHSSPHQS(p) EDEEE as substrate incubated for 40 mins in presence of [gamma-33P]-ATP by scintillation counting method	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1198348	Antitumor activity against human COLO205-F1756 clone 4 cells harboring APC mutant xenografted in CrTac:NCr-Foxn1nu mouse assessed as reduction in flux normalized to tumor weight at 70 mg/kg, po bid for 9 days relative to control	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
AID1198311	Tmax in NMRI mouse at 0.2 mg/kg, iv	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
AID1731820	Growth inhibition human WI38 cells after 72 hrs by resazurin or MTT assay	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1731868	Toxicity in BALB/c mouse assessed as monocytes at 70 mg/kg, po administered once daily for 7 days and measured on day 15 by flow cytometric analysis	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1295752	Clearance in NMRI mouse at 0.2 mg/kg, iv and 0.5 mg/kg po by LC-MS/MS analysis	2016	Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3	Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.
AID1852094	Antiproliferative activity against human HT-29 cells assessed as cell viability incubated for 48 hrs by MTT assay
AID1198329	Inhibition of CYP2C9 (unknown origin)	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
AID1198328	Thermodynamic aqueous solubility of the compound in phosphate buffer at pH 7.4	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
AID1731866	Toxicity in BALB/c mouse assessed as dendritic cells at 70 mg/kg, po administered once daily for 7 days and measured on day 15 by flow cytometric analysis	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1198314	Tmax in NMRI mouse at 0.5 mg/kg, po	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
AID1198347	Antitumor activity against human COLO205-F1756 clone 4 cells harboring APC mutant xenografted in CrTac:NCr-Foxn1nu mouse assessed as reduction in tumor weight at 70 mg/kg, po bid for 9 days relative to control	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
AID1731805	Growth inhibition human MOLM-13 cells after 72 hrs by resazurin or MTT assay	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1295775	Inhibition of WNT pathway activation in human LS174T cells expressing beta-catenin mutant	2016	Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3	Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.
AID1852096	Antiproliferative activity against human CT26 cells assessed as cell viability incubated for 48 hrs by MTT assay
AID1731812	Growth inhibition human COLO 205 cells after 72 hrs by resazurin or MTT assay	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1198308	Intrinsic clearance in human liver microsome at 1 uM preincubated for 5 mins by LC-MS analysis	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
AID1295754	Volume of distribution in NMRI mouse assessed as liver blood flow at 0.2 mg/kg, iv and 0.5 mg/kg, po by LC-MS/MS analysis	2016	Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3	Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.
AID1852095	Antiproliferative activity against human SW480 cells assessed as cell viability incubated for 48 hrs by MTT assay
AID1852092	Inhibition of CDK8 (unknown origin) assessed as inhibition rate
AID1198349	Drug uptake in tumor of human COLO205-F1756 clone 4 cells harboring APC mutant xenografted CrTac:NCr-Foxn1nu mouse at 70 mg/kg, po bid for 9 days measured after 2 to 6 hrs	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
AID1295761	Clearance in Beagle dog at 0.2 mg/kg, iv and 0.5 mg/kg, po by LC-MS/MS analysis relative to liver blood flow	2016	Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3	Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.
AID1198342	Inhibition of ligand-induced WNT3A signaling in human PA-1 cells harboring TCF preincubated for 6 hrs before ligand addition measured after 24 hrs by luciferase reporter assay	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
AID1731815	Growth inhibition human PANC-1 cells after 72 hrs by resazurin or MTT assay	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1198338	Inhibition of WNT signaling in human 7dF3 cells assessed as inhibition of endogenous cMYC transcription up to 9.1 uM after 2 hrs by RT-PCR analysis relative to control	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
AID1731865	Toxicity in BALB/c mouse assessed as B cells at 70 mg/kg, po administered once daily for 7 days and measured on day 15 by flow cytometric analysis	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1198331	Inhibition of CYP2C8 (unknown origin)	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
AID1198345	Effect on TCF1 level in human COLO205-F1756 clone 4 cells harboring APC mutant and TCF/LEF responsive element at 350 nM by immunoblotting	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
AID1295770	Thermodynamic solubility of compound	2016	Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3	Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.
AID1198317	Clearance in Wistar rat at 0.2 mg/kg, iv	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
AID1295781	Half life in NMRI mouse at 0.2 mg/kg, iv and 0.5 mg/kg, po by LC-MS/MS analysis	2016	Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3	Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.
AID1295764	Binding affinity to His-tagged CDK8 (unknown origin) after 60 mins by FRET based lanthascreen binding assay	2016	Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3	Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.
AID1198306	Intrinsic clearance in mouse liver microsome at 1 uM preincubated for 5 mins by LC-MS analysis	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
AID1295766	Intrinsic clearance in rat microsomes preincubated for 5 mins followed by addition of 1.5 mM of NADPH measured after 5 to 30 mins by LC-MS/MS analysis	2016	Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3	Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.
AID1198336	Inhibition of GSK3alpha (unknown origin)	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
AID1198321	Half life in Wistar rat at 0.2 mg/kg, iv	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
AID1198335	Efflux ratio for apparent permeability in human Caco2 cells after 2 hrs by LC-MS/MS analysis	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
AID1731802	Growth inhibition human Kasumi-1 cells after 72 hrs by resazurin or MTT assay	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1731803	Growth inhibition human KG-1 cells after 72 hrs by resazurin or MTT assay	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1731859	Toxicity in BALB/c mouse assessed as vasculitis in blood vessels at 70 mg/kg, po administered once daily for 7 days and measured on day 15	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1295777	Inhibition of WNT pathway activation in human SW480 cells expressing APC mutant	2016	Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3	Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.
AID1731814	Growth inhibition human HT-29 cells after 72 hrs by resazurin or MTT assay	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1198323	AUC in Wistar rat at 0.5 mg/kg, po	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
AID1731838	Cmax in Sprague-Dawley rat at 20 mg/kg, po measured up to 24 hrs by LC-MS/MS analysis	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1198312	AUC in NMRI mouse at 0.2 mg/kg, iv	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
AID1295769	Kinetic solubility of compound	2016	Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3	Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.
AID1731811	Growth inhibition human U-937 cells after 72 hrs by resazurin or MTT assay	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1852097	Cytotoxicity against human GES1 cells assessed as cell viability incubated for 48 hrs by MTT assay
AID1198340	Inhibition of basal WNT signaling in human LS174T cells harboring beta-catenin mutant and TCF/LEF responsive element after 24 hrs by firefly luciferase reporter assay	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
AID1198341	Inhibition of basal WNT signaling in human SW480 cells harboring APC mutant	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
AID1198316	Oral bioavailability in NMRI mouse at 0.5 mg/kg	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
AID1198350	Drug uptake in plasma of human COLO205-F1756 clone 4 cells harboring APC mutant xenografted CrTac:NCr-Foxn1nu mouse at 70 mg/kg, po bid for 9 days measured after 2 to 6 hrs	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
AID1198320	AUC in Wistar rat at 0.2 mg/kg, iv	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
AID1731864	Toxicity in BALB/c mouse assessed as increase in dead splenocytes at 70 mg/kg, po administered once daily for 7 days and measured on day 15 by flow cytometric analysis	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1295749	Binding affinity to CDK8/CDK19 in human 7dF3 cells preincubated for 2 hrs followed by addition 10 uM of beta-oestradiol measured after 24 hrs by luciferase reporter gene assay	2016	Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3	Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.
AID1731819	Growth inhibition human MDA-MB-453 cells after 72 hrs by resazurin or MTT assay	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1198343	Inhibition of WNT signaling in human RKO-F1522 cells after 24 hrs by EF1alpha promoter-driven luciferase reporter assay	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
AID1198324	Oral bioavailability in Wistar rat at 0.5 mg/kg	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
AID1731834	Half life in Sprague-Dawley rat at 5 mg/kg, iv measured up to 24 hrs by LC-MS/MS analysis	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1295771	Plasma clearance in wild type mouse	2016	Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3	Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.
AID1731818	Growth inhibition human MDA-MB-231 cells after 72 hrs by resazurin or MTT assay	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1731809	Growth inhibition human PL-21 cells after 72 hrs by resazurin or MTT assay	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1731840	Half life in Sprague-Dawley rat at 20 mg/kg, po measured up to 24 hrs by LC-MS/MS analysis	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1295759	Clearance in Wistar rat at 0.2 mg/kg, iv and 0.5 mg/kg po by LC-MS/MS analysis relative to liver blood flow	2016	Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3	Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.
AID1731862	Toxicity in BALB/c mouse assessed as pathological alterations in left femora at 70 mg/kg, po administered once daily for 7 days and measured on day 15	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1295750	Efflux ratio in human Caco2 cells after 2 hrs by LC-MS/MS analysis	2016	Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3	Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.
AID1295756	Clearance in Beagle dog at 0.2 mg/kg, iv and 0.5 mg/kg, po by LC-MS/MS analysis	2016	Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3	Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.
AID1295782	Half life in Wistar rat at 0.2 mg/kg, iv and 0.5 mg/kg po by LC-MS/MS analysis	2016	Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3	Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.
AID1295760	Volume of distribution in Wistar rat assessed as liver blood flow at 0.2 mg/kg, iv and 0.5 mg/kg po by LC-MS/MS analysis	2016	Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3	Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.
AID1731799	Inhibition of human GSKbeta H350L mutant (2 to 3nd residues) using YRRAAVPPSPSLSRHSSPHQS(p) EDEEE as substrate incubated for 40 mins in presence of [gamma-33P]-ATP by scintillation counting method	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1731867	Toxicity in BALB/c mouse assessed as granulocytes at 70 mg/kg, po administered once daily for 7 days and measured on day 15 by flow cytometric analysis	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1198307	Intrinsic clearance in rat liver microsome at 1 uM preincubated for 5 mins by LC-MS analysis	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
AID1731832	Cmax in Sprague-Dawley rat at 5 mg/kg, iv measured up to 24 hrs by LC-MS/MS analysis	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1731872	Growth inhibition human T47D cells after 72 hrs by resazurin or MTT assay	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1731817	Growth inhibition human MCF7 cells after 72 hrs by resazurin or MTT assay	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1731777	Growth inhibition of human MV4-11 cells after 72 hrs by resazurin staining based assay	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1295765	Binding affinity to human CDK19 (1 to 502 amino acid residues)/Cyclin C (1 to 283 amino acid residues) by reporter displacement assay	2016	Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3	Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.
AID1198346	Effect on TCF4 level in human COLO205-F1756 clone 4 cells harboring APC mutant and TCF/LEF responsive element at 350 nM by immunoblotting	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
AID1295757	Oral bioavailability NMRI mouse assessed as liver blood flow at 0.5 mg/kg by LC-MS/MS analysis	2016	Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3	Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.
AID1731863	Toxicity in BALB/c mouse assessed as pathological alterations in lung at 70 mg/kg, po administered once daily for 7 days and measured on day 15	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1295776	Inhibition of WNT ligand dependent WNT pathway activation in human PA1 cells	2016	Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3	Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.
AID1198313	Half life in NMRI mouse at 0.2 mg/kg, iv	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
AID1295768	Intrinsic clearance in human microsomes preincubated for 5 mins followed by addition of 1.5 mM of NADPH measured after 5 to 30 mins by LC-MS/MS analysis	2016	Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3	Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.
AID1731860	Toxicity in BALB/c mouse assessed as infiltration of inflammatory cells at 70 mg/kg, po administered once daily for 7 days and measured on day 15	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1731871	Toxicity in BALB/c mouse assessed as increase in CD3-T cells at 70 mg/kg, po administered once daily for 7 days and measured on day 15 by flow cytometric analysis	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1198309	Clearance in NMRI mouse at 0.2 mg/kg, iv	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
AID1731813	Growth inhibition human HCT-116 cells after 72 hrs by resazurin or MTT assay	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1295755	Oral bioavailability in Wistar rat at 0.5 mg/kg by LC-MS/MS analysis	2016	Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3	Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.
AID1295772	Drug excretion in wild type mouse feces assessed as parent compound remaining level	2016	Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3	Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.
AID1295762	Volume of distribution in Beagle dog at 0.2 mg/kg, iv and 0.5 mg/kg, po by LC-MS/MS analysis	2016	Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3	Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.
AID1198332	Inhibition of CYP3A4 (unknown origin)	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
AID1731837	Clearance in Sprague-Dawley rat at 5 mg/kg, iv measured up to 24 hrs by LC-MS/MS analysis	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1198327	Kinetic solubility of the compound in phosphate buffer at pH 7.4	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
AID1731870	Toxicity in BALB/c mouse assessed as neutrophils at 70 mg/kg, po administered once daily for 7 days and measured on day 15 by flow cytometric analysis	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1731816	Growth inhibition human A2780 cells after 72 hrs by resazurin or MTT assay	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1731869	Toxicity in BALB/c mouse assessed as macrophages at 70 mg/kg, po administered once daily for 7 days and measured on day 15 by flow cytometric analysis	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1731833	Tmax in Sprague-Dawley rat at 5 mg/kg, iv measured up to 24 hrs by LC-MS/MS analysis	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1198318	Volume of distribution at steady state in Wistar rat at 0.2 mg/kg, iv	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
AID1198325	Inhibition of GST-tagged TNKS1 (1023 to 1327 aa) (unknown origin) after 90 mins by HTRF assay	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
AID1731857	Toxicity in BALB/c mouse assessed as interstitial pneumonitis in lung at 70 mg/kg, po administered once daily for 7 days and measured on day 15	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1731836	Volume of distribution at steady state in Sprague-Dawley rat at 5 mg/kg, iv measured up to 24 hrs by LC-MS/MS analysis	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1198344	Inhibition of basal WNT signaling in human COLO205-F1756 clone 4 cells harboring APC mutant and TCF/LEF responsive element after 24 hrs by firefly luciferase reporter assay	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
AID1731835	AUC in Sprague-Dawley rat at 5 mg/kg, iv measured up to 24 hrs by LC-MS/MS analysis	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1295767	Intrinsic clearance in mouse microsomes preincubated for 5 mins followed by addition of 1.5 mM of NADPH measured after 5 to 30 mins by LC-MS/MS analysis	2016	Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3	Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.
AID1731841	AUC in Sprague-Dawley rat at 20 mg/kg, po measured up to 24 hrs by LC-MS/MS analysis	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1731858	Toxicity in BALB/c mouse assessed as increase in number of alveolar macrophages at 70 mg/kg, po administered once daily for 7 days and measured on day 15	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1295784	Lipophilicity, logD of the compound	2016	Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3	Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.
AID1295783	Half life in Beagle dog at 0.2 mg/kg, iv and 0.5 mg/kg, po by LC-MS/MS analysis	2016	Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3	Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.
AID1852091	Inhibition of CDK8 (unknown origin) assessed as inhibition rate at 200 nM relative to control
AID1731842	Oral bioavailability in Sprague-Dawley rat at 20 mg/kg measured up to 24 hrs by LC-MS/MS analysis	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1198315	AUC in NMRI mouse at 0.5 mg/kg, po	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
AID1731800	Inhibition of human full length PKCtheta using histone H1 as substrate incubated for 40 mins in presence of [gamma-33P]-ATP by scintillation counting method	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1731808	Inhibition of CDK8 in human MV4-11 cells assessed as reduction in STAT1 phosphorylation at s727 residues at 1 to 5 times of GI50 concentration after 2 hrs by Western blot analysis	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1731861	Toxicity in BALB/c mouse assessed as destruction of vessel walls at 70 mg/kg, po administered once daily for 7 days and measured on day 15	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1295758	Clearance in Wistar rat at 0.2 mg/kg, iv and 0.5 mg/kg po by LC-MS/MS analysis	2016	Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3	Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.
AID1198326	Inhibition of GST-tagged TNKS2 (873 to 1166 aa) (unknown origin) after 90 mins by HTRF assay	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
AID1295773	Plasma clearance in P-gp KO mouse	2016	Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3	Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.
AID1198296	Inhibition of WNT signaling in human 7dF3 cells preincubated for 2 hrs before beta-estradiol addition measured after 24 hrs by luciferase reporter assay	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
AID1731839	Tmax in Sprague-Dawley rat at 20 mg/kg, po measured up to 24 hrs by LC-MS/MS analysis	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1731807	Effect on total STAT1 level in human MV4-11 cells at 1 to 5 times of GI50 concentration after 2 hrs by Western blot analysis	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1295774	Drug excretion in P-gp knock-out mouse feces assessed as parent compound remaining level	2016	Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3	Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.
AID1198339	Inhibition of WNT signaling in human 7dF3 cells assessed as inhibition of endogenous cMYC transcription after 2 hrs by RT-PCR analysis	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
AID1852093	Antiproliferative activity against human HCT-116 cells assessed as cell viability incubated for 48 hrs by MTT assay
AID1295763	Oral bioavailability in Beagle dog at 0.5 mg/kg by LC-MS/MS analysis	2016	Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3	Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.
AID1731806	Growth inhibition human NB4 cells after 72 hrs by resazurin or MTT assay	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1198322	Tmax in Wistar rat at 0.5 mg/kg, po	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
AID1731810	Growth inhibition human THP1 cells after 72 hrs by resazurin or MTT assay	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1198337	Inhibition of GSK3beta (unknown origin)	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
AID1295753	Clearance in NMRI mouse at 0.2 mg/kg, iv and 0.5 mg/kg, po by LC-MS/MS analysis relative to liver blood flow	2016	Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3	Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.
AID1198319	Tmax in Wistar rat at 0.2 mg/kg, iv	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
AID1198310	Volume of distribution at steady state in NMRI mouse at 0.2 mg/kg, iv	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
AID1731776	Inhibition of CDK8/cyclin C (unknown origin) using RBER-IRStide as substrate incubated for 60 mins in presence of [gamma33P]ATP by scintillation counting method	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1731801	Growth inhibition human HL-60 cells after 72 hrs by resazurin or MTT assay	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347414	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Secondary screen by immunofluorescence	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347412	qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1345673	Human cyclin dependent kinase 19 (CDK8 subfamily)	2015	Nature chemical biology, Dec, Volume: 11, Issue:12	A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease.
AID1345661	Human cyclin dependent kinase 8 (CDK8 subfamily)	2015	Nature chemical biology, Dec, Volume: 11, Issue:12	A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	4 (50.00)	24.3611
2020's	4 (50.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	8 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
sorafenib [no description available]	2.11	1	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; phenylureas; pyridinecarboxamide	angiogenesis inhibitor; anticoronaviral agent; antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; ferroptosis inducer; tyrosine kinase inhibitor
abt 869 [no description available]	2.11	1	aromatic amine; indazoles; phenylureas	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
cortistatin a cortistatin A: structure in first source. cortistatin A : A member of the class of cortistatins that is substituted by hydroxy groups at positions 1 and 2, a dimethylamino group at the 3alpha position and an isoquinolin-7-yl group at the 17 position, with double bonds at the 9-11 and 10-19 positions (the 1R,2R,17beta enantiomer).	2.13	1	cortistatins; diol; secondary alcohol
ponatinib [no description available]	2.11	1	(trifluoromethyl)benzenes; acetylenic compound; benzamides; imidazopyridazine; N-methylpiperazine	antineoplastic agent; tyrosine kinase inhibitor

Condition	Relationship Strength	Studies
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.11	1
Colorectal Cancer [description not available]	2.11	1
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	2.11	1
Cancer of Colon [description not available]	2.11	1
Colonic Neoplasms Tumors or cancer of the COLON.	2.11	1
Experimental Neoplasms [description not available]	2.13	1
Benign Neoplasms [description not available]	2.6	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.6	1

CCT251545

Description

Cross-References

Synonyms (32)

Research Excerpts

Bioavailability

Roles (3)

Drug Classes (3)

Protein Targets (13)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (224)

Molecular Functions (40)

Ceullar Components (45)

Bioassays (140)

Research

Studies (8)

Market Indicators

Research Demand Index: 20.07

Study Types

CCT251545

Description

Cross-References

Synonyms (32)

Research Excerpts

Bioavailability

Roles (3)

Drug Classes (3)

Protein Targets (13)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (224)

Molecular Functions (40)

Ceullar Components (45)

Bioassays (140)

Research

Studies (8)

Market Indicators

Research Demand Index: 20.07

Study Types

Related Drugs (4)

Related Conditions (8)